A genetic diagnostic kit and system for predicting the response of patients with depressive disorders to treatment
Through the combination of gene diagnosis kit and social and psychological factor scale, the response of patients with depression disorders to anti-depressive treatment is predicted, and the problem of lack of effective prediction in the existing technology is solved, which improves the accuracy and predictability of treatment and reduces the difficulty of treatment. Sexual depression and mental disability occur.
Patent Information
- Application Number
- CN202111335063.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-11-11
AI Technical Summary
The prior art lacks objective biomarkers that effectively predict the response of patients with depression disorders to antidepressant medications, resulting in about one-third of patients not responding to treatment, which may interrupt treatment and lead to refractory depression and mental disability.
The genotypes of single nucleotide polymorphism sites rs200494044, rs117583613 and rs45437897 were detected through a genetic diagnosis kit combined with a social and psychological factor scale, and depression was predicted using the childhood trauma questionnaire, family environment scale and life event scale. The response of patients with disorders to antidepressant treatment is guided to the addition of other therapies besides antidepressants such as physical therapy and psychotherapy in the initial treatment regimen.
It improves the accuracy and predictability of anti-depressive treatment in patients with depression disorders, reduces the occurrence of refractory depression and mental disability, and screens out predictive combinations through gene and environment interactions, which improves the first-shot cure rate.
Smart Images

Figure BDA0003350208660000051
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biological diagnosis, and specifically provides a gene diagnosis kit and system for predicting the treatment response of patients with depression disorders. Background Art
[0002] Depressive disorder refers to a type of mood disorder caused by various reasons and characterized by a significant and persistent group of depressive symptoms as the main clinical feature. Its core symptoms are low mood and loss of interest that are disproportionate to the situation. Only 0.5% of patients with depressive disorder receive adequate treatment.
[0003] Patients with depressive disorders are affected by multiple factors, including genes, environment, and their interactions. Environmental factors, especially psychosocial factors, affect the prevalence of patients with depressive disorders. For example, childhood and adolescence abuse and / or negative life events before depressive episodes often lead to treatment resistant depression (TRD). In order to identify the genetic factors that affect the efficacy of antidepressants, scholars have conducted pharmacogenetics and made a series of discoveries. For example, polymorphisms of the pharmacokinetics-related gene ABCB1 affect the efficacy of antidepressants. However, studies on pharmacodynamic-related gene polymorphisms have not yet obtained consistent results, such as the serotonergic gene SLC6A4, the serotonin receptor genes 5HTTLPR, HTR1A, and HTR2A, the metabolic enzyme genes MAOA, COMT, and TPH, the glutamatergic gene GRIK4, the neurotrophic factor gene BDNF, and the stress response regulation gene FKBP5. With the advancement of sequencing technology, genome-wide association studies (GWAS) have provided a hypothesis-free approach for pharmacogenomics, but only a few studies have achieved significant differences at the genome-wide level and have not been well validated, such as ITGA9, NRXN3, and AUTS2.
[0004] There are currently no objective biomarkers to predict the efficacy of depressive disorders. About one-third of patients with depressive disorders do not respond to antidepressant drugs, which may lead to some patients interrupting treatment and prolonged treatment, ultimately leading to mental disability and loss of ability to work and live. Summary of the invention
[0005] In order to solve the problems existing in the above-mentioned prior art and improve the accuracy and predictability of the prediction of the efficacy of drugs after taking medicines for patients with depressive disorders, the present invention predicts the patient's response to antidepressant treatment through a genetic diagnosis kit combined with a social psychological factor scale. If it is predicted that the patient will not respond to the treatment, other therapies besides antidepressants, such as physical therapy and psychotherapy, can be added to the initial treatment plan to improve the first cure rate and reduce the occurrence of refractory depression and mental disability.
[0006] One aspect of the present invention provides a system for predicting the antidepressant treatment response of patients with depressive disorders, the system comprising a kit for detecting the genotype of patients with depressive disorders and a social psychological factor scale; the kit and the social psychological factor scale are selected from:
[0007] a) the kit comprises a reagent for detecting the genotype of the single nucleotide polymorphism site rs200494044, and the social psychological factor scale is selected from the Childhood Trauma Questionnaire;
[0008] b) the kit comprises a reagent for detecting the genotype of the single nucleotide polymorphism site rs117583613, and the social psychological factor scale is selected from the family environment scale; or
[0009] c) The kit comprises a reagent for detecting the genotype of the single nucleotide polymorphism site rs45437897, and the social psychological factor scale is selected from the life event scale.
[0010] Furthermore, the Childhood Trauma Questionnaire was selected from the Physical Neglect item in the Childhood Trauma Questionnaire.
[0011] Another aspect of the present invention provides use of the above system in preparing a tool for predicting antidepressant treatment response in patients with depressive disorders.
[0012] In another aspect, the present invention provides a kit for predicting the antidepressant treatment response of patients with depressive disorders, wherein the kit comprises reagents capable of detecting the genotypes of single nucleotide polymorphism sites rs200494044, rs117583613 and rs45437897.
[0013] In another aspect, the present invention provides the use of the above-mentioned kit in preparing a tool for evaluating the treatment response of subjects with abnormally elevated scores on a social psychological factor scale after receiving antidepressant treatment drugs.
[0014] In another aspect, the present invention provides a method for predicting the antidepressant treatment response of a patient with a depressive disorder, the method comprising:
[0015] S1) collecting samples from subjects, and detecting the genotype of the single nucleotide polymorphism site using a kit for detecting the genotype of the single nucleotide polymorphism site;
[0016] S2) Collecting data on the social psychological factors scale of the subjects;
[0017] S3) predicting the antidepressant treatment response of patients with depressive disorders based on the single nucleotide polymorphism site genotype and social psychological factor scale data obtained in step S1);
[0018] Among them, the following subjects responded below average to antidepressant treatment:
[0019] a) If the genotype of the rs200494044 SNP locus is AG or AA, it can be expected that the reduction rate of the Hamilton Depression Rating Scale (HAMD-17) will increase with the decrease of the score of the physical neglect item in the Childhood Trauma Questionnaire after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment;
[0020] b) If the genotype of the rs117583613 SNP locus is AG or AA, it can be expected that after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment, the reduction rate of the Hamilton Depression Rating Scale will increase as the total score of the knowledge score in the family environment scale of the subject decreases;
[0021] c) If the genotype of the rs45437897 SNP locus is TC or TT, it can be expected that after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment, the reduction rate of the Hamilton Depression Rating Scale will increase as the total score of the social and other aspects of the life event scale of the subject decreases;
[0022] The Hamilton Depression Rating Scale score reduction rate=(baseline Hamilton Depression Rating Scale score-post-treatment Hamilton Depression Rating Scale score) / baseline Hamilton Depression Rating Scale score.
[0023] In another aspect, the present invention provides a method for analyzing the effect of the interaction between the genes of patients with depression and their social environment on the treatment effect of patients with depression, the method comprising the following steps:
[0024] S01) Recruiting patients with depressive disorders;
[0025] S02) After the patient is enrolled, the enrollment information is collected, and the collected data includes the patient's blood sample and the social psychological factor assessment form as the baseline data;
[0026] S03) giving the patient an antidepressant treatment regimen, the treatment regimen comprising receiving a single antidepressant treatment for 8 weeks, or receiving a single antidepressant treatment for 8 weeks and adding rTMS treatment in the first 2 weeks;
[0027] S04) The Hamilton Depression Rating Scale scores at baseline, week 2, week 4, and week 8 were calculated;
[0028] S05) performing gene sequencing on the patient's blood sample to obtain the sequence of the candidate gene.
[0029] S06) A linear regression model was used to construct a gene-environment interaction model, with a P value less than 1×10 -7 As screening conditions, the combination of genotypes and social environmental factors that may affect the treatment effect of patients with depressive disorders were screened.
[0030] Furthermore, the criteria for recruiting patients with depressive disorders were as follows: (1) meeting the criteria for non-psychotic depression in the Diagnostic and Statistical Manual of Mental Disorders-Ⅳ (DSM-Ⅳ); (2) Hamilton Depression Rating Scale (17-item Hamilton Depression Rating Scale, HAMD-17) greater than 17; (3) depressive symptoms lasting at least 2 weeks; (4) not receiving medication or other treatment for at least 2 weeks before enrollment; and (5) signing the informed consent form.
[0031] Exclusion criteria were as follows: (1) history of other DSM-ⅣI axis diseases; (2) personality disorder, mental retardation, pregnancy or breastfeeding, organic disease, and other diseases that affect psychiatric assessment; (3) electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) within 6 months after enrollment; (4) contraindications to rTMS; (5) manic episodes in the 12 months before enrollment; (6) patients who needed to change antidepressant medication or had poor compliance after enrollment; (7) patients with serious physical illness; and (8) patients who voluntarily withdrew from the study during the study.
[0032] Further, rTMS treatment parameters were: “figure-8” coil, 1 Hz, 80% motor threshold, targeting the right dorsolateral prefrontal cortex, twice a day, 10 minutes each time, 30 seconds between stimulations, for a total of 14 days.
[0033] Furthermore, the psychosocial factor assessment scale was selected from the Childhood Trauma Questionnaire, the Family Environment Scale, the Social Support Scale, and the Life Events Scale.
[0034] Beneficial Effects
[0035] For the treatment of patients with depressive disorders, this invention proposes for the first time that the interaction between genes and the environment has a predictive effect on treatment. Specifically, three groups of gene-environment interaction factors were screened out from the combination of more than ten environmental factors and more than ten thousand SNP sites, and the patient's response to antidepressant treatment was predicted through a genetic diagnostic kit combined with a social psychological factor scale. DETAILED DESCRIPTION
[0036] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the specific implementation modes of the present invention are described in detail below, but it should not be understood as limiting the applicable scope of the present invention.
[0037] Example
[0038] Study subjects: A total of 1331 patients with depressive disorders were recruited in this study, and 984 patients were finally included for statistical analysis. The inclusion criteria for patients with depressive disorders were: (1) non-psychotic depression in accordance with the Diagnostic and Statistical Manual of Mental Disorders-Ⅳ (DSM-Ⅳ); (2) Hamilton Depression Rating Scale (17-item Hamilton Depression Rating Scale, HAMD-17) greater than 17; (3) depressive symptoms lasting at least 2 weeks; (4) no medication or other treatment for at least 2 weeks before enrollment; (5) signed informed consent. Exclusion criteria were as follows: (1) history of other DSM-ⅣI axis diseases; (2) personality disorder, mental retardation, pregnancy or breastfeeding, organic disease, and other diseases that affect psychiatric assessment; (3) electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) within 6 months after enrollment; (4) contraindications to rTMS; (5) manic episodes in the 12 months before enrollment; (6) patients who needed to change antidepressant medication or had poor compliance after enrollment; (7) patients with serious physical diseases, such as epilepsy, endocrine diseases, blood diseases, and obvious abnormalities of heart, liver, and kidney function; and (8) patients who voluntarily withdrew from the study during the study.
[0039] Antidepressant treatment: According to clinical practice, the patients were enrolled in the group and the enrolment information was collected. The collected data included patient blood samples and the following psychosocial factor assessment form as baseline data. All patients then received a single antidepressant for 8 weeks, or rTMS treatment was added in the first 2 weeks. Except for the use of low-dose benzodiazepine anxiolytics to relieve insomnia, other psychotropic drugs were not allowed, otherwise they were excluded from the group. The rTMS treatment parameters were: "8" shaped coil, 1hz, 80% motor threshold, targeting the right dorsolateral prefrontal cortex, twice a day, 10 minutes each time, 30 seconds between stimulations, for a total of 14 days.
[0040] Social and psychological factors and endpoint event assessment: Social and psychological factors include:
[0041] (1) Childhood trauma questionnaire-short form (CTQ-SF), which includes five dimensions: emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect. The scoring criteria are as follows: a total score of 8 or more for sexual abuse is considered to be sexual abuse; a total score of 13 or more for emotional abuse is considered to be emotional abuse; a total score of 10 or more for physical abuse is considered to be physical abuse; a total score of 10 or more for physical neglect is considered to be physical neglect; and a total score of 15 or more for emotional neglect is considered to be emotional neglect.
[0042] (2) Family environment scale-Chinese version (FES-CV), which includes 10 dimensions, namely cohesion, expressiveness, conflict, independence, achievement, intellectual_cultural, recreational, moral_religious, organization, and control.
[0043] (3) Social support rating scale (SSRS), which includes three dimensions: objective support, subjective support, and support-seeking behavior.
[0044] (4) Life event scale (LES), including positive life events, negative life events, family life events, work events, and social and other aspects.
[0045] End point event: Hamilton Depression Rating Scale (HAMD-17) score at baseline, week 2, week 4, and week 8. HAMD-17 score reduction rate = (baseline - week 8) / baseline.
[0046] Gene sequencing: A total of 1,309 candidate genes were included in this study. The sample source was peripheral blood. The sequencing range of each gene included the exon region, 5' untranslated region (UTR), 3'-UTR, and exon-intron boundary region.
[0047] Statistical analysis: Linear regression model was used to construct the gene-environment interaction model. -07 as a filter condition.
[0048] Results: As shown in the following table:
[0049] (1) rs200494044 interacted with the physical neglect dimension of the Childhood Abuse Scale, affecting the score reduction rate of HAMD-17 in patients with depressive disorders after 8 weeks of treatment;
[0050] (2) rs117583613 interacted with the knowledge dimension of the Family Environment Scale, affecting the score reduction rate of HAMD-17 in patients with depressive disorders after 8 weeks of treatment;
[0051] (3) rs45437897 interacted with the social and other aspects of the life events scale, affecting the reduction rate of HAMD-17 in patients with depressive disorders after 8 weeks of treatment.
[0052]
[0053]
[0054] rs200494044: Location: chr16:2071869 (GRCh38.p13), Allele: G>A
[0055] rs117583613: Location: chr3:48561890 (GRCh38.p13), Allele: G>A
[0056] rs45437897: Location: chr20:46011590 (GRCh38.p13), Allele: C>T
[0057] The P value results show that these three groups of interaction data can be used to predict the treatment effect of patients with depressive disorders after combining the interaction between genes and environment. For patients with rs200494044 SNP locus genotype of AG or AA, the score of the physical neglect item in the Childhood Trauma Questionnaire increased by one unit, and the HAMD-17 score reduction rate decreased by 0.06 units after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment in the first 2 weeks, which predicts that the patient will have a poor treatment effect when taking a single antidepressant.
[0058] Similarly, for patients with rs117583613 SNP locus genotype of AG or AA, for every unit increase in the total score of the knowledge score in the family environment scale, the HAMD-17 score reduction rate decreased by 0.12 units after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment in the first 2 weeks, which can predict that the patient will have a poor treatment effect when taking a single antidepressant.
[0059] For patients with rs45437897 SNP locus genotype of TC or TT, for every unit increase in the total score of social and other aspects of the Life Events Scale, the HAMD-17 score reduction rate decreased by 0.12 units after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment in the first 2 weeks, which can predict that the patient's treatment effect of taking a single antidepressant is poor.
[0060] For patients predicted to have poor efficacy, doctors can be guided to add other therapies besides antidepressants to the initial treatment plan, such as physical therapy and psychotherapy, to improve the first cure rate and reduce the occurrence of refractory depression and mental disability.
[0061] Due to the particularity of the condition of patients with depressive disorders, the efficiency of drug treatment for this disease is much lower than that of other diseases. There have been many reports that drugs for this type of disease cause toxicity to the heart, lungs, liver and kidneys of patients. The present invention proposes for the first time that in addition to the influence of individual genotypes, there are also environmental factors in the prediction of drug efficacy. Genotype and environmental factors complement each other, and their combined effects lead to the influence on the effect of medication. Since the patient's blood and various score sheets are samples or data that can be obtained at the early stage of diagnosis and treatment, these easily obtained data can greatly improve the treatment efficiency of patients with depressive disorders.
Claims
1. A system for predicting the response of patients with depressive disorders to antidepressant treatment, characterized in that: The system comprises a kit for detecting the genotype of a patient with depressive disorder and a social psychological factor scale; the kit and the social psychological factor scale are: a) the kit contains a reagent for detecting the genotype of the single nucleotide polymorphism site rs200494044, and the social psychological factor scale is selected from the physical neglect dimension of the Childhood Trauma Questionnaire, and the allele of rs200494044 is G>A; b) the kit comprises a reagent for detecting the genotype of the single nucleotide polymorphism site rs117583613, and the social psychological factor scale is selected from the knowledge dimension of the family environment scale; rs117583613 allele: G>A; and c) The kit comprises a reagent for detecting the genotype of the single nucleotide polymorphism site rs45437897, and the social psychological factor scale is selected from the social and other aspects of the life event scale, and the rs45437897 allele is: C>T.
2. Use of the system for predicting the antidepressant treatment response of patients with depressive disorders according to claim 1 in preparing a tool for predicting the antidepressant treatment response of patients with depressive disorders; wherein: a) The genotype of the rs200494044 SNP locus is AG or AA, which can predict that the reduction rate of the Hamilton Depression Rating Scale will increase with the decrease of the score of the physical neglect item in the Childhood Trauma Questionnaire after taking a single antidepressant or taking a single antidepressant and adding repetitive transcranial magnetic stimulation (rTMS) treatment; b) The genotype of the rs117583613 SNP locus is AG or AA, which can predict that the reduction rate of the Hamilton Depression Rating Scale will increase with the decrease of the total score of the knowledge score in the family environment scale of the subject after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment; c) The genotype of the rs45437897 SNP locus is TC or TT, which can predict that the reduction rate of the Hamilton Depression Rating Scale will increase with the decrease of the total score of the social and other aspects of the life event scale of the subject after taking a single antidepressant or taking a single antidepressant and adding rTMS treatment; The Hamilton Depression Rating Scale score reduction rate=(baseline Hamilton Depression Rating Scale score-post-treatment Hamilton Depression Rating Scale score) / baseline Hamilton Depression Rating Scale score.
